Company Vectura Group

Equities

VEC

GB00BKM2MW97

Delayed London S.E. Other stock markets 11:35:22 2021-10-18 am EDT			5-day change	1st Jan Change
164.8 ^GBX	-.--%		-.--%	-.--%

Apr. 16	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
2021	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI

Business Summary

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Managers

Managers	Title	Age	Since
Elizabeth Knowles DFI	Director of Finance/CFO	-	-
Anthony Fitzpatrick COO	Chief Operating Officer	-	17-06-30
Geraldine Venthoye CTO	Chief Tech/Sci/R&D Officer	-	16-05-31
John Murphy LAW	General Counsel	70	16-05-31
Sharon Johnson PRN	Corporate Officer/Principal	60	20-02-09

Company contact information

Vectura Group Ltd.

Manning House 22 Carlisle Place

SW1P 1JA, Westminster

+44 12 4966 7700

http://www.vectura.com

Group companies

Name	Category and Sector
Jagotec AG
Vectura Ltd. Vectura Ltd. Medical SpecialtiesHealth Technology Part of Philip Morris International, Inc., Vectura Ltd. is a leading inhalation CDMO that provides innovative inhaled drug development solutions to help bring medicines to market. The private company is based in Chippenham, UK, and has planning permission for a new 10,000-square meter facility on Bristol & Bath Science Park - inhalation center of excellence. Vectura is reimagining healthcare and self-care, transforming the lives of airways disease patients. Founded in 1983, the British company specializes in formulation science, device technology, and inhaled development expertise to bring DPI, PMDI, and nebulizer medicines to market.	Medical Specialties
Vectura Group Services Ltd. Vectura Group Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Philip Morris International, Inc., Vectura Group Services Ltd. provides business support services. The private company is based in London, UK.	Miscellaneous Commercial Services

Sector

This company's sector is not yet available